Oops, looks like you need to register to access this feature.
Select “Keep Exploring” to look around Scholars in Medicine. You have full access to all videos and podcasts for a limited time. Registration is provided at no cost exclusively for healthcare providers.
Sign Up or Log In
SIM - Scholars in Medicine Logo
Login
SIM - Scholars in Medicine Logo
Founding Sponsors
Register

romidepsin

Brand and Other Names: ISTODAX
Mechanism of Action:

Romidepsin inhibits histone deacetylases (HDACs), leading to:

  • Accumulation of acetylated histones
  • Cell cycle arrest and apoptosis in cancer cells.
Indications:

ISTODAX is approved for the treatment of cutaneous T-cell lymphoma (CTCL) in adults who have received at least one prior systemic therapy.

Route: intravenous
Dose:

14 mg/m² IV over 4 hours on Days 1, 8, and 15 of a 28-day cycle.

Adverse Reactions:

Nausea, fatigue, infections, vomiting, anorexia, ECG ST-T changes, dysgeusia, constipation, pruritus.

Contraindication:

None

Warnings and Precautions:

Myelosuppression: Risk of neutropenia, anemia, thrombocytopenia. Monitor blood counts.

Infections: Serious infections including reactivation of EBV and hepatitis B reported.

ECG Changes: Potential for QT prolongation. Monitor electrolytes and ECG in at-risk patients.

Tumor Lysis Syndrome: Especially in patients with advanced disease or high tumor burden.

Embryo-Fetal Toxicity: Can cause fetal harm. Requires contraception during and 1 month post-treatment

See package insert for full prescribing information.